Publikationen, an denen er mitarbeitet Ana María García Osta (43)

2024

  1. Characterization of brain transduction capability of a BBB-penetrant AAV vector in mice, rats and macaques reveals differences in expression profiles

    Gene Therapy, Vol. 31, Núm. 9-10, pp. 455-466

  2. Resilience to structural and molecular changes in excitatory synapses in the hippocampus contributes to cognitive function recovery in Tg2576 mice

    Neural Regeneration Research, Vol. 19, Núm. 9, pp. 2068-2074

  3. The immune system: uncharted pathways between senses and the brain

    Neural Regeneration Research, Vol. 19, Núm. 6, pp. 1173-1174

2023

  1. Docosahexaenoic Acid Ameliorates Contextual Fear Memory Deficits in the Tg2576 Alzheimer’s Disease Mouse Model: Cellular and Molecular Correlates

    Pharmaceutics, Vol. 15, Núm. 1

  2. Improvement of cognitive function in wild-type and Alzheimer´s disease mouse models by the immunomodulatory properties of menthol inhalation or by depletion of T regulatory cells

    Frontiers in Immunology, Vol. 14

2021

  1. Amyloid-driven tau accumulation on mitochondria potentially leads to cognitive deterioration in alzheimer’s disease

    International Journal of Molecular Sciences, Vol. 22, Núm. 21

  2. Identifying the main functional pathways associated with cognitive resilience to alzheimer’s disease

    International Journal of Molecular Sciences, Vol. 22, Núm. 17

2020

  1. GLUT12 Expression in Brain of Mouse Models of Alzheimer’s Disease

    Molecular Neurobiology, Vol. 57, Núm. 2, pp. 798-805

  2. Linking histone deacetylases and phosphodiesterase 5 in novel treatments for Alzheimer’s disease

    Genetics, Neurology, Behavior, and Diet in Dementia: The Neuroscience of Dementia, Volume 2 (Elsevier), pp. 213-226

  3. PLA2G4E, a candidate gene for resilience in Alzheimer´s disease and a new target for dementia treatment

    Progress in Neurobiology, Vol. 191

2019

  1. Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class i Histone Deacetylase Selective Inhibitors

    ACS Chemical Neuroscience, Vol. 10, Núm. 3, pp. 1765-1782

  2. Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles

    ACS Chemical Neuroscience, Vol. 10, Núm. 9, pp. 4076-4101

  3. Taking advantage of the selectivity of histone deacetylases and phosphodiesterase inhibitors to design better therapeutic strategies to treat Alzheimer's disease

    Frontiers in Aging Neuroscience, Vol. 11, Núm. JUN

  4. Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy

    Molecular Therapy - Nucleic Acids, Vol. 16, pp. 26-37

2018

  1. Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 150, pp. 506-524

  2. Immunomodulatory properties of carvone inhalation and its effects on contextual fear memory in mice

    Frontiers in Immunology, Vol. 9, Núm. JAN

  3. Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples

    Neurotherapeutics, Vol. 15, Núm. 3, pp. 742-750

  4. The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma

    Neuro-Oncology, Vol. 20, Núm. 7, pp. 930-941

2017

  1. A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice

    Neuropsychopharmacology, Vol. 42, Núm. 2, pp. 524-539

  2. Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer’s Disease

    ACS Chemical Neuroscience, Vol. 8, Núm. 3, pp. 638-661